Coherus BioSciences (CHRS)
(Real Time Quote from BATS)
$1.66 USD
+0.08 (5.06%)
Updated Jul 26, 2024 12:26 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Coherus BioSciences, Inc. [CHRS]
Reports for Purchase
Showing records 61 - 70 ( 70 total )
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
No Need to Sweat Sandoz Pegfilgrastim Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Things Turn Green as Operating Leverage Materializes; We Raise Price Target to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
It''s Hard to Complain About 113% Quarter-on-Quarter Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
An Innovator in Biosimilars; Initiate at Buy With $28 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Analyst Dinner Provides Insights to UDENYCA''s Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
UDENYCA; a Neulasta Biosimilar Is Now Approved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
UDENCYA Approved in Europe; U.S. Should Be Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and setting a $28 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J